s_id
stringlengths 2
9
| r_id
stringlengths 2
6
| e_id
stringlengths 2
10
| s_label
stringlengths 1
250
| r_label
stringlengths 2
66
| e_label
stringlengths 1
265
|
|---|---|---|---|---|---|
Q37127097 | P2860 | Q77229046 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Nitrosation of uric acid by peroxynitrite. Formation of a vasoactive nitric oxide donor |
Q37127097 | P2860 | Q84578275 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol: novel indications in cardiovascular disease |
Q37127097 | P2860 | Q84494875 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions |
Q37127097 | P2860 | Q68255434 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide |
Q37127097 | P2860 | Q84384051 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Allopurinol-induced DRESS syndrome |
Q37127097 | P2860 | Q83555387 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Febuxostat hypersensitivity |
Q37127097 | P2860 | Q73123213 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes |
Q37127097 | P2860 | Q87289805 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Antihyperuricemic effects of thiadiazolopyrimidin-5-one analogues in oxonate treated rats |
Q37127097 | P2860 | Q89181859 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: an exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study |
Q37127097 | P2860 | Q60711768 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid inhibits renal proximal tubule cell proliferation via at least two signaling pathways involving PKC, MAPK, cPLA2, and NF-κB |
Q37127097 | P2860 | Q87331713 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Design, synthesis and molecular modeling of aloe-emodin derivatives as potent xanthine oxidase inhibitors |
Q37127097 | P2860 | Q85229485 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | A new cycloartane-type triterpenoid saponin xanthine oxidase inhibitor from Homonoia riparia Lour |
Q37127097 | P2860 | Q60637933 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Immunohistochemical localization of xanthine oxidase in human cardiac and skeletal muscle |
Q37127097 | P2860 | Q73403772 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Biotransformation of protocatechuic aldehyde and caffeic acid to vanillin and capsaicin in freely suspended and immobilized cell cultures of Capsicum frutescens |
Q37127097 | P2860 | Q68791382 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Hypouricemia and hyperuricosuria in Laennec cirrhosis |
Q37127097 | P2860 | Q71995282 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Hypochlorite induces lipid peroxidation in blood lipoproteins and phospholipid liposomes |
Q37127097 | P2860 | Q85312726 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Synthesis and xanthine oxidase inhibitory activity of 5,6-dihydropyrazolo/pyrazolo[1,5-c]quinazoline derivatives |
Q37127097 | P2860 | Q85289299 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Synthesis and Biological Evaluation of Novel Aryl-2H-pyrazole Derivatives as Potent Non-purine Xanthine Oxidase Inhibitors |
Q37127097 | P2860 | Q70144052 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression |
Q37127097 | P2860 | Q84617958 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008 |
Q37127097 | P2860 | Q73873383 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | XDH gene mutation is the underlying cause of classical xanthinuria: a second report |
Q37127097 | P2860 | Q87418169 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | cites work | Rhabdomyolysis associated with initiation of febuxostat therapy for hyperuricaemia in a patient with chronic kidney disease |
Q37127097 | P921 | Q49970 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | main subject | hyperuricemia |
Q37127097 | P921 | Q8047 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | main subject | enzyme |
Q37127097 | P921 | Q3271540 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | main subject | mechanism of action |
Q37127097 | P921 | Q427492 | Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview | main subject | enzyme inhibitor |
Q37127111 | P31 | Q101352 | Deats | instance of | family name |
Q37127111 | P282 | Q8229 | Deats | writing system | Latin script |
Q37127111 | P5323 | Q92953148 | Deats | attested in | 2010 United States Census surname index |
Q37127115 | P31 | Q101352 | Brindley | instance of | family name |
Q37127115 | P1889 | Q917359 | Brindley | different from | Brindley |
Q37127115 | P407 | Q1860 | Brindley | language of work or name | English |
Q37127115 | P282 | Q8229 | Brindley | writing system | Latin script |
Q37127115 | P5323 | Q92953148 | Brindley | attested in | 2010 United States Census surname index |
Q37127119 | P31 | Q13442814 | Monocular Deprivation in Mice | instance of | scholarly article |
Q37127119 | P1433 | Q27725732 | Monocular Deprivation in Mice | published in | Bio-protocol |
Q37127119 | P2860 | Q37032417 | Monocular Deprivation in Mice | cites work | Downregulation of cortical inhibition mediates ocular dominance plasticity during the critical period |
Q37127119 | P2860 | Q51282197 | Monocular Deprivation in Mice | cites work | RECEPTIVE FIELDS OF CELLS IN STRIATE CORTEX OF VERY YOUNG, VISUALLY INEXPERIENCED KITTENS |
Q37127119 | P50 | Q58331188 | Monocular Deprivation in Mice | author | Ya-tang Li |
Q37127120 | P31 | Q101352 | Chorey | instance of | family name |
Q37127120 | P282 | Q8229 | Chorey | writing system | Latin script |
Q37127120 | P5323 | Q92953148 | Chorey | attested in | 2010 United States Census surname index |
Q37127135 | P31 | Q13442814 | Antiatherogenic functionality of high density lipoprotein: how much versus how good | instance of | scholarly article |
Q37127135 | P31 | Q7318358 | Antiatherogenic functionality of high density lipoprotein: how much versus how good | instance of | review article |
Q37127135 | P1433 | Q26842628 | Antiatherogenic functionality of high density lipoprotein: how much versus how good | published in | Journal of Atherosclerosis and Thrombosis |
Q37127135 | P921 | Q28350 | Antiatherogenic functionality of high density lipoprotein: how much versus how good | main subject | lipoprotein |
Q37127135 | P50 | Q91944002 | Antiatherogenic functionality of high density lipoprotein: how much versus how good | author | Alan T. Remaley |
Q37127140 | P31 | Q13442814 | Mechanism of pi-induced vascular calcification | instance of | scholarly article |
Q37127140 | P31 | Q7318358 | Mechanism of pi-induced vascular calcification | instance of | review article |
Q37127140 | P1433 | Q26842628 | Mechanism of pi-induced vascular calcification | published in | Journal of Atherosclerosis and Thrombosis |
Q37127156 | P31 | Q13442814 | Autonomous control of oxygenation | instance of | scholarly article |
Q37127156 | P31 | Q7318358 | Autonomous control of oxygenation | instance of | review article |
Q37127156 | P1433 | Q15766545 | Autonomous control of oxygenation | published in | Journal of Trauma |
Q37127156 | P407 | Q1860 | Autonomous control of oxygenation | language of work or name | English |
Q37127158 | P31 | Q13442814 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | instance of | scholarly article |
Q37127158 | P1433 | Q15758529 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | published in | British Journal of Radiology |
Q37127158 | P2860 | Q33844873 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiob |
Q37127158 | P2860 | Q35749557 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Loss of biological effect in prolonged fraction delivery |
Q37127158 | P2860 | Q33989975 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix |
Q37127158 | P2860 | Q36838126 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Repair capacity and kinetics for human mucosa and epithelial tumors in the head and neck: clinical data on the effect of changing the time interval between multiple fractions per day in radiotherapy. |
Q37127158 | P2860 | Q42618261 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer |
Q37127158 | P2860 | Q52391669 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Derivation and application of equations describing the effects of fractionated protracted irradiation, based on multiple and incomplete repair processes. Part I. Derivation of equations. |
Q37127158 | P2860 | Q48458975 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Clinical outcome for chemoradiotherapy in carcinoma of the cervix. |
Q37127158 | P2860 | Q51755084 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Effects of very low dose-rate (90)Sr/(90)Y exposure on the acute moist desquamation response of pig skin. |
Q37127158 | P2860 | Q51935118 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Radiobiological modelling of dose-gradient effects in low dose rate, high dose rate and pulsed brachytherapy. |
Q37127158 | P2860 | Q52372933 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Two components of repair in irradiated kidney colony forming cells. |
Q37127158 | P2860 | Q52340800 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Monte Carlo aided dosimetry of the microselectron pulsed and high dose-rate 192Ir sources. |
Q37127158 | P2860 | Q58376374 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Compensation for changes in dose-rate in radical low-dose-rate brachytherapy: a radiobiological analysis of a randomised clinical trial |
Q37127158 | P2860 | Q59138882 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Point: Why choose pulsed-dose-rate brachytherapy for treating gynecologic cancers? |
Q37127158 | P2860 | Q80944705 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study |
Q37127158 | P2860 | Q73865645 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Is pulsed dose rate more damaging to spinal cord of rats than continuous low dose rate? |
Q37127158 | P2860 | Q80813867 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Retrospective dosimetric comparison of low-dose-rate and pulsed-dose-rate intracavitary brachytherapy using a tandem and mini-ovoids |
Q37127158 | P2860 | Q79611036 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Brachytherapy for carcinoma of the cervix: a Canadian survey of practice patterns in a changing era |
Q37127158 | P2860 | Q62269576 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | The effect of alternative biological modelling parameters (α/β and half time of repair T1/2) on reported EQD2 values in the treatment of advanced cervical cancer |
Q37127158 | P2860 | Q85633782 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | The implementation of the Gynaecological Groupe Européen de Curiethérapie - European Society for Therapeutic Radiology and Oncology radiobiology considerations in the conversion of low dose rate to pulsed dose rate treatment schedules for gynaecolog |
Q37127158 | P2860 | Q73930726 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Radiation tolerance of rat spinal cord to pulsed dose rate (PDR-) brachytherapy: the impact of differences in temporal dose distribution |
Q37127158 | P2860 | Q69685712 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Repair capacity and kinetics of human skin during fractionated radiotherapy: erythema, desquamation, and telangiectasia after 3 and 5 year's follow-up |
Q37127158 | P2860 | Q70572133 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Recovery from radiation damage in mouse lung: interpretation in terms of two rates of repair |
Q37127158 | P2860 | Q72899748 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Repair rate in mouse lung after clinically relevant radiation doses per fraction |
Q37127158 | P2860 | Q71251979 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | The influence of the number of fractions and bi-exponential repair kinetics on biological equivalence in pulsed brachytherapy |
Q37127158 | P2860 | Q73292311 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Biological effect of pulsed dose rate brachytherapy with stepping sources if short half-times of repair are present in tissues |
Q37127158 | P2860 | Q73801853 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | cites work | Pulsed brachytherapy as a substitute for continuous low dose rate: comment on Chen, Huang, Hall, and Brenner's paper |
Q37127158 | P407 | Q1860 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | language of work or name | English |
Q37127158 | P921 | Q896687 | Biphasic and monophasic repair: comparative implications for biologically equivalent dose calculations in pulsed dose rate brachytherapy of cervical carcinoma | main subject | brachytherapy |
Q37127191 | P31 | Q13442814 | Randomized controlled trials: methodological concepts and critique | instance of | scholarly article |
Q37127191 | P31 | Q7318358 | Randomized controlled trials: methodological concepts and critique | instance of | review article |
Q37127191 | P1433 | Q7104844 | Randomized controlled trials: methodological concepts and critique | published in | Orthopaedic Nursing (journal) |
Q37127191 | P407 | Q1860 | Randomized controlled trials: methodological concepts and critique | language of work or name | English |
Q37127191 | P921 | Q1436668 | Randomized controlled trials: methodological concepts and critique | main subject | randomized controlled trial |
Q37127212 | P31 | Q13442814 | Determinants of disability in chronic musculoskeletal health conditions: a literature review | instance of | scholarly article |
Q37127212 | P1433 | Q5412742 | Determinants of disability in chronic musculoskeletal health conditions: a literature review | published in | European Journal of Physical and Rehabilitation Medicine |
Q37127212 | P921 | Q12131 | Determinants of disability in chronic musculoskeletal health conditions: a literature review | main subject | disability |
Q37127214 | P31 | Q13442814 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | instance of | scholarly article |
Q37127214 | P1433 | Q925779 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | published in | Journal of Molecular Biology |
Q37127214 | P2860 | Q36726739 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | cites work | SRP keeps polypeptides translocation-competent by slowing translation to match limiting ER-targeting sites |
Q37127214 | P2860 | Q36915705 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | cites work | Following translation by single ribosomes one codon at a time. |
Q37127214 | P2860 | Q29619435 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | cites work | A "silent" polymorphism in the MDR1 gene changes substrate specificity |
Q37127214 | P2860 | Q33911236 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | cites work | Nascent peptide-mediated translation elongation arrest coupled with mRNA degradation in the CGS1 gene of Arabidopsis |
Q37127214 | P2860 | Q37356413 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | cites work | A nascent polypeptide domain that can regulate translation elongation |
Q37127214 | P2860 | Q34182941 | Electrostatics in the ribosomal tunnel modulate chain elongation rates | cites work | Functional analysis of an archaebacterial voltage-dependent K+ channel |